The case study examines Moderna's journey in democratizing artificial intelligence (AI), particularly generative AI, across its workforce. It details the company's "digital-first, AI-focused" approach, including the rollout of OpenAI's ChatGPT Enterprise to all employees and encouraging them to build and share custom GPTs. The case highlights the tension between fostering innovation and speed through widespread AI adoption and managing the associated risks, such as inaccuracies ("hallucinations") and the potential misuse of custom GPTs in critical processes like performance reviews and clinical trial dosing recommendations. It explores Moderna's efforts to establish governance practices to balance these concerns as leadership contemplates whether to centralize control over GPT development or maintain the current democratized model, and if they need to inform regulators about the integration of GPTs into core processes.